J

Johnson & Johnson

Makes prescription drugs and medical devices

Facilities Engineer - Planning

Full-TimePosted on 10/20/2026Deadline 10/28/26
No salary listed
Mid
Bachelor's
Alajuela Province, Grecia, Costa Rica
In PersonPrimarily on-site; limited domestic or international travel based on business needs.
Facilities OperationsFacilities Management

About the job

Requirements
  • A university bachelor's degree in Mechanical, Electrical, Electromechanical, Industrial, Maintenance Engineering, or another related engineering or technical discipline is required.
  • Two to four years of related experience in Facilities, maintenance planning, maintenance engineering, asset management, maintenance systems, reliability, technical services, or related functions is required.
  • Experience working with maintenance management systems, maintenance records, preventive maintenance programs, or asset information is required.
  • Experience within regulated manufacturing environments is required.
  • Intermediate to advanced English proficiency, both written and verbal, is required.
  • Practical knowledge of Facilities systems, utilities, infrastructure, and maintenance processes.
  • Knowledge of maintenance planning, preventive maintenance, asset management, and maintenance management systems.
  • Working knowledge of maintenance documentation, records management, and applicable compliance requirements.
  • Ability to analyze maintenance data, performance indicators, equipment history, and operational trends.
  • Ability to coordinate multiple maintenance activities, priorities, stakeholders, and operational requirements.
  • Strong technical writing and documentation skills.
  • Strong attention to detail and commitment to data accuracy and integrity.
  • Proficiency with Microsoft Office applications and ability to work effectively with Facilities and business systems.
  • Availability for limited domestic or international travel based on business needs.
Responsibilities
  • Owns assigned Facilities maintenance programs and workstreams, ensuring maintenance requirements, job plans, schedules, documentation, and execution controls are established and maintained in accordance with applicable procedures and operational requirements.
  • Develops, reviews, optimizes, and updates preventive maintenance activities, job plans, frequencies, schedules, and associated technical documentation based on equipment history, operational requirements, technical data, risk, and maintenance performance.
  • Analyzes maintenance execution, schedules, backlog, compliance, equipment performance, and maintenance indicators to identify risks, establish priorities, and develop corrective and improvement actions.
  • Evaluates maintenance risks, equipment condition, recurring failures, overdue activities, and operational constraints, and develops recommendations and mitigation actions to maintain equipment and Facilities system reliability.
  • Provides technical support for troubleshooting Facilities equipment and systems, including evaluation of equipment history, maintenance records, technical documentation, and recurring issues to support problem resolution and prevent recurrence.
  • Coordinates maintenance requirements and priorities with Facilities personnel, contractors, service providers, and other stakeholders to support maintenance execution and operational requirements.
  • Supports and coordinates technical maintenance requirements for contractors and service providers, reviews service documentation and technical deliverables, and follows up on identified technical or compliance gaps.
  • Manages assigned asset information and maintenance requirements, including equipment data, maintenance strategies, asset changes, technical documentation, and lifecycle records.
  • Plans and coordinates calibration activities for applicable Facilities equipment and instrumentation, including scheduling, documentation, execution follow-up, and compliance with applicable requirements.
  • Evaluates spare parts and maintenance, repair, and operations requirements, including identification of critical spare parts, inventory needs, material availability, and potential risks to planned and corrective maintenance execution.
  • Reviews maintenance records, work orders, and technical documentation for completeness, accuracy, traceability, and compliance with applicable requirements, and coordinates resolution of identified gaps.
  • Evaluates maintenance and asset management requirements associated with new equipment, modifications, projects, and system changes, ensuring applicable maintenance, spare parts, documentation, and operational readiness requirements are addressed prior to turnover.
  • Participates in Facilities projects, equipment implementation, system changes, commissioning, turnover, and operational readiness activities, providing technical input related to maintainability, maintenance requirements, asset information, and lifecycle support.
  • Provides technical guidance to Facilities personnel on maintenance requirements, job plans, documentation practices, equipment information, troubleshooting, and execution priorities within assigned areas of responsibility.
  • Supports audits, inspections, investigations, and compliance activities associated with Facilities maintenance programs, systems, equipment, and documentation, including evaluation and follow-up of identified gaps and corrective actions.
  • Collaborates with Facilities, Engineering, Quality, Environmental Health and Safety, Manufacturing, Procurement, and other applicable functions to resolve maintenance-related issues and support reliability, compliance, operational continuity, and business objectives.
  • Identifies opportunities for standardization, efficiency, reliability, and continuous improvement within Facilities maintenance processes and leads or supports implementation of approved improvements.
  • Communicates business-related issues or opportunities to the next management level.
  • Follows applicable Company guidelines related to Health, Safety, and Environmental practices.
  • Ensures personal and Company compliance with all Federal, State, local, and Company regulations, policies, and procedures.
  • Performs other duties as assigned.
Desired Qualifications
  • Experience with calibration programs, spare parts management, maintenance data analysis, or continuous improvement activities is preferred.
  • Knowledge of Access Control, facility management, facility management software, premises management, security planning, standard operating procedures, and project reporting.
  • Ability to apply data-driven decision making, conflict resolution, problem solving, organizing, proactive behavior, service excellence, and collaboration with subject matter experts.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.